304 related articles for article (PubMed ID: 28089587)
1. Development of
Kimura H; Matsuda H; Ogawa Y; Fujimoto H; Toyoda K; Fujita N; Arimitsu K; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H
Bioorg Med Chem; 2017 Feb; 25(4):1406-1412. PubMed ID: 28089587
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of an
Kimura H; Fujita N; Kanbe K; Matsuda H; Watanabe H; Arimitsu K; Fujimoto H; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H
Bioorg Med Chem; 2017 Oct; 25(20):5772-5778. PubMed ID: 28927802
[TBL] [Abstract][Full Text] [Related]
3. [
Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
[TBL] [Abstract][Full Text] [Related]
4. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
[TBL] [Abstract][Full Text] [Related]
5. Structure-Activity Relationships and Pharmacokinetics of
Iikuni S; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Aug; 19(8):2832-2839. PubMed ID: 35757958
[TBL] [Abstract][Full Text] [Related]
6. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
[TBL] [Abstract][Full Text] [Related]
7. Development of an
Iikuni S; Kamei I; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Mar; 19(3):1019-1027. PubMed ID: 35138111
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.
Xu Q; Zhu C; Xu Y; Pan D; Liu P; Yang R; Wang L; Chen F; Sun X; Luo S; Yang M
J Drug Target; 2015; 23(9):813-20. PubMed ID: 25758750
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of
Kimura H; Ogawa Y; Fujimoto H; Mukai E; Kawashima H; Arimitsu K; Toyoda K; Fujita N; Yagi Y; Hamamatsu K; Murakami T; Murakami A; Ono M; Nakamoto Y; Togashi K; Inagaki N; Saji H
Bioorg Med Chem; 2018 Jan; 26(2):463-469. PubMed ID: 29273416
[TBL] [Abstract][Full Text] [Related]
10. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 receptor imaging for localization of insulinomas.
Christ E; Wild D; Forrer F; Brändle M; Sahli R; Clerici T; Gloor B; Martius F; Maecke H; Reubi JC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4398-405. PubMed ID: 19820010
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
[TBL] [Abstract][Full Text] [Related]
13. Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys
Senica K; Tomazic A; Skvarca A; Kolenc Peitl P; Mikolajczak R; Hubalewska-Dydejczyk A; Lezaic L
Mol Imaging Biol; 2020 Feb; 22(1):165-172. PubMed ID: 31098984
[TBL] [Abstract][Full Text] [Related]
14. Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.
Bauman A; Valverde IE; Fischer CA; Vomstein S; Mindt TL
J Nucl Med; 2015 Oct; 56(10):1569-74. PubMed ID: 26251418
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Specific Activity by Multichelation of Exendin-3 Leads To Improved Image Quality and In Vivo Beta Cell Imaging.
Joosten L; Brom M; Peeters H; Heskamp S; Béhé M; Boerman O; Gotthardt M
Mol Pharm; 2018 Feb; 15(2):486-494. PubMed ID: 29226686
[TBL] [Abstract][Full Text] [Related]
16. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
[TBL] [Abstract][Full Text] [Related]
17. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.
Wicki A; Wild D; Storch D; Seemayer C; Gotthardt M; Behe M; Kneifel S; Mihatsch MJ; Reubi JC; Mäcke HR; Christofori G
Clin Cancer Res; 2007 Jun; 13(12):3696-705. PubMed ID: 17575235
[TBL] [Abstract][Full Text] [Related]
18. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
Wild D; Wicki A; Mansi R; Béhé M; Keil B; Bernhardt P; Christofori G; Ell PJ; Mäcke HR
J Nucl Med; 2010 Jul; 51(7):1059-67. PubMed ID: 20595511
[TBL] [Abstract][Full Text] [Related]
19. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma.
Kiesewetter DO; Gao H; Ma Y; Niu G; Quan Q; Guo N; Chen X
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):463-73. PubMed ID: 22170321
[TBL] [Abstract][Full Text] [Related]
20. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals.
Wu H; Liang S; Liu S; Pan Y; Cheng D; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):701-8. PubMed ID: 23652208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
